Biomaterial Database

[The role of new dihydropyridine calcium channel blockers in the treatment of hypertension]. 2003

A Coca

UI	MeSH Term	Description	Entries
D006973	Hypertension	Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008660	Metabolism	The chemical reactions in living organisms by which energy is provided for vital processes and activities and new material is assimilated.	Anabolism,Catabolism,Metabolic Concepts,Metabolic Phenomena,Metabolic Processes,Metabolic Phenomenon,Metabolic Process,Metabolism Concepts,Metabolism Phenomena,Process, Metabolic,Processes, Metabolic,Concept, Metabolic,Concept, Metabolism,Concepts, Metabolic,Concepts, Metabolism,Metabolic Concept,Metabolism Concept,Phenomena, Metabolic,Phenomena, Metabolism,Phenomenon, Metabolic
D002121	Calcium Channel Blockers	A class of drugs that act by selective inhibition of calcium influx through cellular membranes.	Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000959	Antihypertensive Agents	Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.	Anti-Hypertensive,Anti-Hypertensive Agent,Anti-Hypertensive Drug,Antihypertensive,Antihypertensive Agent,Antihypertensive Drug,Anti-Hypertensive Agents,Anti-Hypertensive Drugs,Anti-Hypertensives,Antihypertensive Drugs,Antihypertensives,Agent, Anti-Hypertensive,Agent, Antihypertensive,Agents, Anti-Hypertensive,Agents, Antihypertensive,Anti Hypertensive,Anti Hypertensive Agent,Anti Hypertensive Agents,Anti Hypertensive Drug,Anti Hypertensive Drugs,Anti Hypertensives,Drug, Anti-Hypertensive,Drug, Antihypertensive,Drugs, Anti-Hypertensive,Drugs, Antihypertensive
D015337	Multicenter Studies as Topic	Works about controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children.	Multicenter Trials,Multicentre Studies as Topic,Multicentre Trials,Multicenter Trial,Multicentre Trial,Trial, Multicenter,Trial, Multicentre,Trials, Multicenter,Trials, Multicentre
D020746	Calcium Channels, L-Type	Long-lasting voltage-gated CALCIUM CHANNELS found in both excitable and non-excitable tissue. They are responsible for normal myocardial and vascular smooth muscle contractility. Five subunits (alpha-1, alpha-2, beta, gamma, and delta) make up the L-type channel. The alpha-1 subunit is the binding site for calcium-based antagonists. Dihydropyridine-based calcium antagonists are used as markers for these binding sites.	Dihydropyridine Receptors,L-Type Calcium Channels,L-Type VDCC alpha-1 Subunit,L-Type Voltage-Dependent Calcium Channel,Long-Lasting Calcium Channel,Long-Lasting Calcium Channels,Receptors, Dihydropyridine,Dihydropyridine Receptor,L-Type Calcium Channel,L-Type VDCC,L-Type VDCC alpha-2 Subunit,L-Type VDCC beta Subunit,L-Type VDCC delta Subunit,L-Type VDCC gamma Subunit,L-Type Voltage-Dependent Calcium Channels,Calcium Channel, L-Type,Calcium Channel, Long-Lasting,Calcium Channels, L Type,Calcium Channels, Long-Lasting,Channel, Long-Lasting Calcium,L Type Calcium Channel,L Type Calcium Channels,L Type VDCC,L Type VDCC alpha 1 Subunit,L Type VDCC alpha 2 Subunit,L Type VDCC beta Subunit,L Type VDCC delta Subunit,L Type VDCC gamma Subunit,L Type Voltage Dependent Calcium Channel,L Type Voltage Dependent Calcium Channels,Long Lasting Calcium Channel,Long Lasting Calcium Channels,Receptor, Dihydropyridine,VDCC, L-Type